Methodological considerations in cost of prostate cancer studies: A systematic review

Value in Health

Volumn 11, Issue 5, 2008, Pages 878-885

  Molinier, Laurent ^a,b,h   Bauvin, Eric ^a,c   Combescure, Christophe ^d,e   Castelli, Christel ^d   Rebillard, Xavier ^f   Soulié, Michel ^a,b   Daurès, Jean Pierre ^d,e   Grosclaude, Pascale ^a,g  

^a INSERM   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

^d UNIV MONTPELLIER   (France)

^e NÎMES UNIVERSITY HOSPITAL   (France)

^f Clinique Beausoleil   (France)

^g Registre des cancers du Tarn   (France)

^h Hôtel Dieu Saint Jacques   (France)

Author keywords

Cost of illness; Economic evaluation; Prostate cancer

Indexed keywords

CONSENSUS; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; METHODOLOGY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY ANALYSIS;

EID: 52649094403     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2008.00327.x     Document Type: Review

References (41)

1. Wiseman V, Mooney G. Burden of illness estimates for priority setting: a debate revisited. Health Policy 1998 43 : 243 51.
2. Koopmanschap MA. Cost-of-illness studies. Useful for health policy? Pharmacoeconomics 1998 14 : 143 8.
3. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes (3rd ed.). Oxford : Oxford University Press, 2005.
4. Drummond M. Cost-of-illness studies: a major headache? Pharmacoeconomics 1992 2 : 1 4.
5. Rice DP. Cost of illness studies: what is good about them? Inj Prev 2000 6 : 177 9.
6. Tarricone R. Cost-of-illness analysis. What room in health economics? Health Policy 2006 77 : 51 63.
7. Ament A, Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy 1993 26 : 29 42.
8. Ruchlin HS, Pellissier JM. An economic overview of prostate carcinoma. Cancer 2001 92 : 2796 810.
9. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. CA Cancer J Clin 2002 52 : 23 47.
10. Brandeis J, Pashos CL, Henning JM, Litwin MS. A nationwide charge comparison of the principal treatments for early stage prostate carcinoma. Cancer 2000 89 : 1792 9.
11. Samant RS, Dunscombe PB, Roberts GH. A cost-outcome analysis of long-term adjuvant goserelin in addition to radiotherapy for locally advanced prostate cancer. Urol Oncol 2003 2 : 171 7.
12. Sennfält K, Carlsson P, Thorfinn J, et al. Technological changes in the management of prostate cancer result in increased healthcare costs. A retrospective study in a defined Swedish population. Scand J Urol Nephrol 2003 37 : 226 31.
13. Grover SA, Zowall H, Coupal L, Krahn MD. Prostate cancer: 12. The economic burden. Can Med Assoc J 1999 160 : 685 90.
14. Grover SA, Coupal L, Zowall H, et al. The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000 162 : 987 92.
15. National Institute for Clinical Excellence. Guide to the Methods of Technology Appraisal. London : NICE, 2004.
16. Johannesson M. Theory and Methods of Economic Evaluation of Health Care. London : Kluwer Academic Publishers, 1996.
17. Koopmanschap MA, Rutten FF. Indirect costs in economic studies: confronting the confusion. Pharmacoeconomics 1993 4 : 446 54.
18. Koopmanschap MA, Rutten FF. A practical guide for calculating indirect costs of disease. Pharmacoeconomics 1996 10 : 460 6.
19. Birnbaum H. Friction-cost method as an alternative to the human-capital approach in calculating indirect costs. Pharmacoeconomics 2005 23 : 103 4.
20. Agro KE, Bradley CA, Mittmann N, et al. Sensitivity analysis in health economic and pharmacoeconomic studies. An appraisal of the literature. Pharmacoeconomics 1997 11 : 75 88.
21. Segel JE. Cost-of-Illness Studies - A Primer. RTI-UNC Center of Excellence in Health Promotion Economics, 2006.
22. Gerard K. Cost-utility in practice: a policy maker's guide to the state of the art. Health Policy 1992 21 : 249 79.
23. Carlsson P, Hjertberg H, Jönsson B, Varenhorst E. The cost of prostatic cancer in a defined population. Scand J Urol Nephrol 1989 23 : 93 6.
24. Koopmanschap MA, van Roijen L, Bonneux L, Barendregt JJ. Current and future costs of cancer. Eur J Cancer 1994 30 : 60 5.
25. Borre M, Nerstrom B, Overgaard J. The dilemma of prostate cancer-a growing human and economic burden irrespective of treatment strategies. Acta Oncol 1997 36 : 681 7.
26. Chamberlain J, Melia J, Moss S, Brown J. The diagnosis, management, treatment and costs of prostate cancer in England and Wales. Health Technol Assess 1997 1 : 1 53.
27. Haillot O, Villers A, Soulié M, Baron JC. Dépistage du cancer de la prostate (IV). Approche économique: les coûts des tests de dépistage et des traitements. Prog Urol 1998 8 : 517 23.
28. Holmberg H, Carlsson P, Kalman D, Varenhorst E. Impact on health service costs of medical technologies used in management of prostatic cancer. Scand J Urol Nephrol 1998 32 : 195 9.
29. Groot MT, Boeken Kruger CG, et al. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Eur Urol 2003 43 : 226 32.
30. Norlund A, Alvegard T, Lithman T, et al. Prostate cancer. Prevalence-based healthcare costs. Scand J Urol Nephrol 2003 37 : 371 5.
31. Riley GF, Potosky AL, Lubitz JD, Kessler LG. Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis. Med Care 1995 33 : 828 41.
32. Litwin MS, Pasta DJ, Stoddard ML, et al. Epidemiological trends and financial outcomes in radical prostatectomy among Medicare beneficiaries, 1991-1993. J Urology 1998 160 : 445 8.
33. Max W, Rice DP, Sung HY, et al. The economic burden of prostate cancer, California, 1998. Cancer 2002 94 : 2906 13.
34. Chang S, Long SR, Kutikova L, et al. Estimating the cost of cancer: results on the basis of claims data analyses for cancer patients diagnosed with seven types of cancer during 1999-2000. J Clin Oncol 2004 22 : 3524 30.
35. Maynard A. Economic evaluation techniques in healthcare: reinventing the wheel? Pharmacoeconomics 1997 11 : 115 8.
36. Maynard A, McDaid D. Evaluating health interventions: exploiting the potential. Health Policy 2003 63 : 215 26.
37. Bloom BS, Bruno DJ, Maman DY, Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision making. Pharmacoeconomics 2001 19 : 207 13.
38. Berthelot JM, Will BP, Evans WK, et al. Decision framework for chemotherapeutic interventions for metastatic non-small-cell lung cancer. J Natl Cancer Inst 2000 92 : 1321 9.
39. Chouaid C, Molinier L, Combescure C, et al. Economics of the clinical management of lung cancer in France: an analysis using a Markov model. Br J Cancer 2004 90 : 397 402.
40. Vergnenègre A, Molinier L, Combescure C, et al. Les composantes du coût des stratégies de prise en charge du cancer du poumon en France. Rev Mal Respir 2004 21 : 501 10.
41. Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ Working Party on Economic Evaluation. BMJ 1996 313 : 275 83.